top of page

Nanomerics CSO delivers the 2024 Annual Anne McLaren lecture

London, United Kingdom April 24th 2024. 

Nanomerics Ltd., a private speciality pharmaceutical company today announced that Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer delivered the Anne McLaren Lecture at University College London (UCL), London, United Kingdom.  Dame Anne McLaren (26 April 1927 – 7 July 2007) was a British reproductive biologist, a trailblazing female scientist and a pioneer of techniques still used today in in vitro fertilisation (IVF).  The lecture honours women scientists and is given every year in a British university by a senior British woman scientist.  During the lecture, Uchegbu spoke about her pioneering work in the area of the medicines design.  She spoke of the nanotechnology developed in her laboratory that reliably controls drug transport in vivo.    Work on the pharmaceutical use of Nanomerics’ Molecular Envelope Technology (MET) as a non-irritant ocular penetration enhancer was showcased in the lecture as was the ability of Nanomerics’ MET to deliver drugs to the retina using eye drops.  Nanomerics’ MET enables the efficient delivery of drugs to the front and back of the eye using transparent and oil-free eye drops.  Nanomerics’ MET has been used to formulate eye drops such as: OC134, indicated for severe allergic eye disease and OC137, indicated for the treatment of retinal diseases.   

Nanomerics is currently executing an OC134 Phase I clinical trial project.  The conclusion of  trial will transform the company to a clinical stage company and enable Nanomerics’ MET to be used for a variety of ophthalmic active pharmaceutical ingredients.  Positive results from this clinical study will allow the company to fully exploit Nanomerics’ MET and deliver the potential benefits of this technology to patients with ocular conditions.  Nanomerics has a pipeline of ophthalmic medicine candidates.   

Nanomerics’ MET also underpins a number of Nanomerics’ central nervous system assets.  Noteworthy among these is Envelta™, a nasal spray powder, which is being developed as a pain therapeutic.  Envelta™ has been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX).  Envelta™ is being developed by Virpax Pharmaceuticals in collaboration with the US National Institutes of Health (NIH).  Nanomerics also has other collaborations with companies aiming to develop new medicines using its MET.   

Nanomerics is based in  state of the art laboratories in North London.  Nanomerics’ Chief Scientific Officer, Professor Ijeoma F. Uchegbu, says, “it was a real honour to be selected to give the annual Anne McLaren lecture this year and I thank the selection committee for their endorsement of our work.”   


bottom of page